title: Developments in modulating protein function for effective target validation.
abstract: The targets of more than 95% of clinically approved drugs are proteins. Thus, the plethora of targets derived from genomics and proteomics efforts must be validated at the protein level. However, most of the preferred target validation technologies are gene- or transcript-based. Protein-based or proteinetic approaches, which are more relevant to determine target druggability, are now emerging.:
authors: Xerion Pharmaceuticals AG, Sauerbruchstrasse 50, 81377 Munich, Germany. Electronic address:l.ilag@xerion-pharma.com.
authors: Leodevico L
authors: LL
authors: Ilag